Now that Axsome Therapeutics Inc’s volume has hit 0.82 million, investors get a glimpse of its size.

Axsome Therapeutics Inc (NASDAQ: AXSM) kicked off on Monday, down -4.17% from the previous trading day, before settling in for the closing price of $90.73. Over the past 52 weeks, AXSM has traded in a range of $64.11-$105.00.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 88.16%. While this was happening, its average annual earnings per share was recorded -3.05%. With a float of $39.61 million, this company’s outstanding shares have now reached $48.44 million.

The extent of productivity of a business whose workforce counts for 545 workers is very important to gauge. In terms of profitability, gross margin is 90.55%, operating margin of -90.84%, and the pretax margin is -91.97%.

Axsome Therapeutics Inc (AXSM) Insider Updates

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Axsome Therapeutics Inc is 18.26%, while institutional ownership is 79.16%. The most recent insider transaction that took place on Sep 11 ’24, was worth 1,005,871. In this transaction Director of this company sold 11,016 shares at a rate of $91.31, taking the stock ownership to the 10,002 shares. Before that another transaction happened on Sep 11 ’24, when Company’s Director proposed sale 11,016 for $91.31, making the entire transaction worth $1,005,843.

Axsome Therapeutics Inc (AXSM) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.87 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -3.05% per share during the next fiscal year.

Axsome Therapeutics Inc (NASDAQ: AXSM) Trading Performance Indicators

Take a look at Axsome Therapeutics Inc’s (AXSM) current performance indicators. Last quarter, stock had a quick ratio of 2.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.45.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.54, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -1.51 in one year’s time.

Technical Analysis of Axsome Therapeutics Inc (AXSM)

The latest stats from [Axsome Therapeutics Inc, AXSM] show that its last 5-days average volume of 0.67 million was superior to 0.61 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 16.03%. Additionally, its Average True Range was 3.95.

During the past 100 days, Axsome Therapeutics Inc’s (AXSM) raw stochastic average was set at 44.95%, which indicates a significant increase from 10.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.92% in the past 14 days, which was lower than the 36.96% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $93.39, while its 200-day Moving Average is $83.82. Now, the first resistance to watch is $89.64. This is followed by the second major resistance level at $92.33. The third major resistance level sits at $94.59. If the price goes on to break the first support level at $84.68, it is likely to go to the next support level at $82.42. Assuming the price breaks the second support level, the third support level stands at $79.73.

Axsome Therapeutics Inc (NASDAQ: AXSM) Key Stats

The company with the Market Capitalisation of 4.21 billion has total of 48,462K Shares Outstanding. Its annual sales at the moment are 270,600 K in contrast with the sum of -239,240 K annual income. Company’s last quarter sales were recorded 104,760 K and last quarter income was -64,600 K.